终止冠昊生物再融资审核；歌礼迎专利挑战｜健讯daily

Group 1 - The National Healthcare Security Administration has included the commercial health insurance innovative drug directory in the adjustment plan for the first time, marking a significant shift in the directory's design logic and industry positioning [1] - The commercial insurance companies will exit the price negotiation process, and the directory will transition to a "recommended list," with the healthcare department taking the lead in drug access and price confidentiality negotiations [1] Group 2 - Kedi Group's new drug finasteride spray has been approved for marketing in China, aimed at treating androgenetic alopecia [3] - Puxiang Health has submitted a listing application to the Hong Kong Stock Exchange, reporting revenues of approximately 255 million yuan, 422 million yuan, and 500 million yuan for the years 2022, 2023, and 2024 respectively [5] - Ruisi Technology has completed a multi-million A2 round financing, which will focus on product development and market expansion [6] - TIDE Pharmaceutical has officially listed on the Hong Kong Stock Exchange, raising approximately 514 million HKD through the issuance of 16.8 million H shares [7] - Ruike Bio has signed a product licensing cooperation agreement with Biological E for its recombinant nine-valent HPV vaccine REC603 [8] Group 3 - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, a significant recovery from a loss of 10.36 million yuan in the same period last year, driven by international business growth and cost control [10] - Geli Pharmaceutical is facing a patent challenge from Shiyao Group regarding its ASC30 drug, which is a GLP-1 receptor agonist for weight loss, highlighting the competitive landscape in the multi-billion dollar weight loss drug market [12] - The Shenzhen Stock Exchange has terminated the review of Guanhao Biological's refinancing application, following the company's withdrawal of its application [14] - Peking University Medicine is facing operational disruptions due to protests from retired employees over housing and welfare issues, impacting the company's normal operations [15]